1
|
Wang X, DeFilippis RA, Leung YK, Shah NP, Li HY. N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants. Bioorg Chem 2024; 143:106966. [PMID: 37995643 DOI: 10.1016/j.bioorg.2023.106966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2023] [Revised: 11/07/2023] [Accepted: 11/10/2023] [Indexed: 11/25/2023]
Abstract
Activating mutations within FLT3 make up 30 % of all newly diagnosed acute myeloid leukemia (AML) cases, with the most common mutation being an internal tandem duplication (FLT3-ITD) in the juxtamembrane region (25 %). Currently, two generations of FLT3 kinase inhibitors have been developed, with three inhibitors clinically approved. However, treatment of FLT3-ITD mutated AML is limited due to the emergence of secondary clinical resistance, caused by multiple mechanism including on-target FLT3 secondary mutations - FLT3-ITD/D835Y and FLT3-ITD/F691L being the most common, as well as the off-target activation of alternative pathways including the BCR-ABL pathway. Through the screening of imidazo[1,2-a]pyridine derivatives, N-(3-methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine (compound 1) was identified as an inhibitor of both the FLT3-ITD and BCR-ABL pathways. Compound 1 potently inhibits clinically related leukemia cell lines driven by FLT3-ITD, FLT3-ITD/D835Y, FLT3-ITD/F691L, or BCR-ABL. Studies indicate that it mediates proapoptotic effects on cells by inhibiting FLT3 and BCR-ABL pathways, and other possible targets. Compound 1 is more potent against FLT3-ITD than BCR-ABL, and it may have other possible targets; however, compound 1 is first step for further optimization for the development of a balanced FLT3-ITD/BCR-ABL dual inhibitor for the treatment of relapsed FLT3-ITD mutated AML with multiple secondary clinical resistant subtypes such as FLT3-ITD/D835Y, FLT3-ITD/F691L, and cells co-expressing FLT3-ITD and BCR-ABL.
Collapse
Affiliation(s)
- Xiuqi Wang
- Department of Biochemistry and Molecular Biology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Rosa Anna DeFilippis
- Division of Hematology/Oncology, University of California, San Francisco, CA, USA
| | - Yuet-Kin Leung
- Department of Pharmacology & Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Neil P Shah
- Division of Hematology/Oncology, University of California, San Francisco, CA, USA
| | - Hong-Yu Li
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
| |
Collapse
|
2
|
Wang X, DeFilippis RA, Weldemichael T, Gunaganti N, Tran P, Leung YK, Shah NP, Li HY. An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L. Eur J Med Chem 2024; 264:115977. [PMID: 38056299 DOI: 10.1016/j.ejmech.2023.115977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 11/07/2023] [Accepted: 11/18/2023] [Indexed: 12/08/2023]
Abstract
FLT3 activating mutations are detected in approximately 30 % of newly diagnosed acute myeloid leukemia (AML) cases, most commonly consisting of internal tandem duplication (ITD) mutations in the juxtamembrane region. Recently, several FLT3 inhibitors have demonstrated clinical activity and three are currently approved - midostaurin, quizartinib, and gilteritinib. Midostaurin is a first-generation FLT3 inhibitor with minimal activity as monotherapy. Midostaurin lacks selectivity and is only approved by the USFDA for use in combination with other chemotherapy agents. The second-generation inhibitors quizartinib and gilteritinib display improved specificity and selectivity, and have been approved for use as monotherapy. However, their clinical efficacies are limited in part due to the emergence of drug-resistant FLT3 secondary mutations in the tyrosine kinase domain at positions D835 and F691. Therefore, in order to overcome drug resistance and further improve outcomes, new compounds targeting FLT3-ITD with secondary mutants are urgently needed. In this study, through the structural modification of a reported compound Ling-5e, we identified compound 24 as a FLT3 inhibitor that is equally potent against FLT3-ITD and the clinically relevant mutants FLT3-ITD/D835Y, and FLT3-ITD/F691L. Its inhibitory effects were demonstrated in both cell viability assays and western blots analyses. When tested against cell lines lacking activating mutations in FLT3, no non-specific cytotoxicity effect was observed. Interestingly, molecular docking results showed that compound 24 may adopt different binding conformations with FLT3-F691L compared to FLT3, which may explain its retained activity against FLT3-ITD/F691L. In summary, compound 24 has inhibition potency on FLT3 comparable to gilteritinib, but a more balanced inhibition on FLT3 secondary mutations, especially FLT3-ITD/F691L which is gilteritinib resistant. Compound 24 may serve as a promising lead for the drug development of either primary or relapsed AML with FLT3 secondary mutations.
Collapse
Affiliation(s)
- Xiuqi Wang
- Department of Biochemistry and Molecular Biology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Rosa Anna DeFilippis
- Division of Hematology/Oncology, University of California, San Francisco, CA, USA
| | - Tsigereda Weldemichael
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Naresh Gunaganti
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Phuc Tran
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Yuet-Kin Leung
- Department of Pharmacology & Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Neil P Shah
- Division of Hematology/Oncology, University of California, San Francisco, CA, USA
| | - Hong-Yu Li
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
| |
Collapse
|
3
|
Peytam F, Emamgholipour Z, Mousavi A, Moradi M, Foroumadi R, Firoozpour L, Divsalar F, Safavi M, Foroumadi A. Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review. Bioorg Chem 2023; 140:106831. [PMID: 37683538 DOI: 10.1016/j.bioorg.2023.106831] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 08/16/2023] [Accepted: 08/30/2023] [Indexed: 09/10/2023]
Abstract
Considering the fundamental role of protein kinases in the mechanism of protein phosphorylation in critical cellular processes, their dysregulation, especially in cancers, has underscored their therapeutic relevance. Imidazopyridines represent versatile scaffolds found in abundant bioactive compounds. Given their structural features, imidazopyridines have possessed pivotal potency to interact with different protein kinases, inspiring researchers to carry out numerous structural variations. In this comprehensive review, we encompass an extensive survey of the design and biological evaluations of imidazopyridine-based small molecules as potential agents targeting diverse kinases for anticancer applications. We describe the structural elements critical to inhibitory potency, elucidating their key structure-activity relationships (SAR) and mode of actions, where available. We classify these compounds into two groups: Serine/threonine and Tyrosine inhibitors. By highlighting the promising role of imidazopyridines in kinase inhibition, we aim to facilitate the design and development of more effective, targeted compounds for cancer treatment.
Collapse
Affiliation(s)
- Fariba Peytam
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Zahra Emamgholipour
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Alireza Mousavi
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Mahfam Moradi
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Roham Foroumadi
- Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Loghman Firoozpour
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Fatemeh Divsalar
- Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
| | - Maliheh Safavi
- Department of Biotechnology, Iranian Research Organization for Science and Technology, Tehran, Iran
| | - Alireza Foroumadi
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
4
|
Yeslam Saeed Atif H, Mohsin M, Durrani AN. Highly Efficient Microwave-Assisted Synthesis of 2-Arylimidazo[1,2-a]Pyridine-3-Carbaldehydes in PEG-400. Polycycl Aromat Compd 2022. [DOI: 10.1080/10406638.2022.2154369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
| | - Mohammad Mohsin
- Department of Chemistry, Rafiq Zakaria College for Women, Aurangabad (M.S.), India
| | - Ayesha N. Durrani
- Department of Chemistry, Rafiq Zakaria College for Women, Aurangabad (M.S.), India
| |
Collapse
|
5
|
Kumbhar VV, Khairnar BB, Chaskar MG, Pawar RA, Gugale GS. Synthetic strategies in development of 3-aroylimidazo[1,2-a]pyridines and 2-aroylimidazo[1,2-a]pyridines: A decade update. SYNTHETIC COMMUN 2022. [DOI: 10.1080/00397911.2022.2056057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Vikrant V. Kumbhar
- Department of Chemistry, PDEA’s Prof. Ramkrishna More College, Pune, India
- Interdisciplinary School of Science (IDSS), Savitribai Phule Pune University, Pune, India
| | - Bhushan B. Khairnar
- Department of Chemistry, PDEA’s Prof. Ramkrishna More College, Pune, India
- Interdisciplinary School of Science (IDSS), Savitribai Phule Pune University, Pune, India
| | - Manohar G. Chaskar
- Department of Chemistry, PDEA’s Prof. Ramkrishna More College, Pune, India
| | - Ramdas A. Pawar
- Department of Chemistry, PDEA’s Prof. Ramkrishna More College, Pune, India
| | - Gulab S. Gugale
- Department of Chemistry, PDEA’s Prof. Ramkrishna More College, Pune, India
- Department of Chemistry, Haribhai V. Desai College, Pune, India
| |
Collapse
|
6
|
Lima MLSO, Braga CB, Becher TB, Odriozola‐Gimeno M, Torrent‐Sucarrat M, Rivilla I, Cossío FP, Marsaioli AJ, Ornelas C. Fluorescent Imidazo[1,2‐
a
]pyrimidine Compounds as Biocompatible Organic Photosensitizers that Generate Singlet Oxygen: A Potential Tool for Phototheranostics. Chemistry 2021; 27:6213-6222. [DOI: 10.1002/chem.202004957] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Indexed: 01/12/2023]
Affiliation(s)
- Maria L. S. O. Lima
- Institute of Chemistry University of Campinas—Unicamp Campinas 13083-861 Sao Paulo Brazil
- Present address: Instituto Federal da Bahia IFBA—Campus Juazeiro 48918-900 Juazeiro, BA Brasil
| | - Carolyne B. Braga
- Institute of Chemistry University of Campinas—Unicamp Campinas 13083-861 Sao Paulo Brazil
| | - Tiago B. Becher
- Institute of Chemistry University of Campinas—Unicamp Campinas 13083-861 Sao Paulo Brazil
| | - Mikel Odriozola‐Gimeno
- Department of Organic Chemistry I Centro de Innovación en Quimica Avanzada (ORFEO-CINQA) Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), and Donostia International Physics Center (DIPC) Po Manuel Lardizabal 3 20018 Donostia/San Sebastián Spain
| | - Miquel Torrent‐Sucarrat
- Department of Organic Chemistry I Centro de Innovación en Quimica Avanzada (ORFEO-CINQA) Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), and Donostia International Physics Center (DIPC) Po Manuel Lardizabal 3 20018 Donostia/San Sebastián Spain
- Ikerbasque Basque Foundation for Science Ma Diaz de Haro 3 Bilbao 48013 Spain
| | - Iván Rivilla
- Department of Organic Chemistry I Centro de Innovación en Quimica Avanzada (ORFEO-CINQA) Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), and Donostia International Physics Center (DIPC) Po Manuel Lardizabal 3 20018 Donostia/San Sebastián Spain
| | - Fernando P. Cossío
- Department of Organic Chemistry I Centro de Innovación en Quimica Avanzada (ORFEO-CINQA) Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), and Donostia International Physics Center (DIPC) Po Manuel Lardizabal 3 20018 Donostia/San Sebastián Spain
| | - Anita J. Marsaioli
- Institute of Chemistry University of Campinas—Unicamp Campinas 13083-861 Sao Paulo Brazil
| | - Catia Ornelas
- Institute of Chemistry University of Campinas—Unicamp Campinas 13083-861 Sao Paulo Brazil
| |
Collapse
|
7
|
Chen Q, Chen S, Wu H, Zeng X, Chen W, Sun G, Wang Z. Application of 2-Aminopyridines in the Synthesis of Five- and Six-Membered Azaheterocycles. CHINESE J ORG CHEM 2021. [DOI: 10.6023/cjoc202104011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
Lakkaniga NR, Zhang L, Belachew B, Gunaganti N, Frett B, Li HY. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. Eur J Med Chem 2020; 203:112589. [PMID: 32717530 DOI: 10.1016/j.ejmech.2020.112589] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 06/01/2020] [Accepted: 06/08/2020] [Indexed: 12/22/2022]
Abstract
Aurora Kinase B is a serine-threonine kinase known to be overexpressed in several cancers, with no inhibitors approved for clinical use. Herein, we present the discovery and optimization of a series of novel quinazoline-based Aurora Kinase B inhibitors. The lead inhibitor SP-96 shows sub-nanomolar potency in Aurora B enzymatic assays (IC50 = 0.316 ± 0.031 nM). We identified the important pharmacophore features resulting in selectivity against receptor tyrosine kinases. Particularly, SP-96 shows >2000 fold selectivity against FLT3 and KIT which is important for normal hematopoiesis. This could diminish the adverse effect of neutropenia reported in the clinical trials of the Aurora B inhibitor Barasertib, which inhibits FLT3 and KIT in addition to Aurora B. Enzyme kinetics of SP-96 shows non-ATP-competitive inhibition which makes it a first-in-class inhibitor. Further, SP-96 shows selective growth inhibition in NCI60 screening, including inhibition of MDA-MD-468, a Triple Negative Breast Cancer cell line.
Collapse
Affiliation(s)
- Naga Rajiv Lakkaniga
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
| | - Lingtian Zhang
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
| | - Binyam Belachew
- Department of Biochemistry and Molecular Biology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
| | - Naresh Gunaganti
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
| | - Brendan Frett
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
| | - Hong-Yu Li
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
| |
Collapse
|
9
|
Kim C, Kim E. Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors. Curr Med Chem 2020; 26:7623-7640. [PMID: 29932031 DOI: 10.2174/0929867325666180622143548] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 04/27/2018] [Accepted: 05/30/2018] [Indexed: 01/16/2023]
Abstract
Rational drug design is accomplished through the complementary use of structural biology and computational biology of biological macromolecules involved in disease pathology. Most of the known theoretical approaches for drug design are based on knowledge of the biological targets to which the drug binds. This approach can be used to design drug molecules that restore the balance of the signaling pathway by inhibiting or stimulating biological targets by molecular modeling procedures as well as by molecular dynamics simulations. Type III receptor tyrosine kinase affects most of the fundamental cellular processes including cell cycle, cell migration, cell metabolism, and survival, as well as cell proliferation and differentiation. Many inhibitors of successful rational drug design show that some computational techniques can be combined to achieve synergistic effects.
Collapse
Affiliation(s)
- Cheolhee Kim
- College of Pharmacy, Chosun University, Gwangju 61452, Korea
| | - Eunae Kim
- College of Pharmacy, Chosun University, Gwangju 61452, Korea
| |
Collapse
|
10
|
Lee J, Ghosh D, Kuo Y, Lee HM. Dimetallic Palladium‐NHC Complexes: Synthesis, Characterization, and Catalytic Application for Direct C−H Arylation Reaction of Heteroaromatics with Aryl Chlorides. Adv Synth Catal 2019. [DOI: 10.1002/adsc.201901189] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Jhen‐Yi Lee
- Department of Chemistry National Changhua University of Education Changhua 50058 Taiwan
| | - Debalina Ghosh
- Department of Chemistry National Changhua University of Education Changhua 50058 Taiwan
| | - Ya‐Ting Kuo
- Department of Chemistry National Changhua University of Education Changhua 50058 Taiwan
| | - Hon Man Lee
- Department of Chemistry National Changhua University of Education Changhua 50058 Taiwan
| |
Collapse
|
11
|
Naresh G, Lakkaniga NR, Kharbanda A, Yan W, Frett B, Li H. Use of Imidazo[1,2‐
a
]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction. European J Org Chem 2019. [DOI: 10.1002/ejoc.201801430] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Gunaganti Naresh
- Department of Pharmaceutical Sciences College of Pharmacy University of Arkansas for Medical Sciences 4301 W Markham St. 72205 Little Rock Arkansas USA
| | - Naga Rajiv Lakkaniga
- Department of Pharmaceutical Sciences College of Pharmacy University of Arkansas for Medical Sciences 4301 W Markham St. 72205 Little Rock Arkansas USA
| | - Anupreet Kharbanda
- Department of Pharmaceutical Sciences College of Pharmacy University of Arkansas for Medical Sciences 4301 W Markham St. 72205 Little Rock Arkansas USA
| | - Wei Yan
- Department of Pharmaceutical Sciences College of Pharmacy University of Arkansas for Medical Sciences 4301 W Markham St. 72205 Little Rock Arkansas USA
| | - Brendan Frett
- Department of Pharmaceutical Sciences College of Pharmacy University of Arkansas for Medical Sciences 4301 W Markham St. 72205 Little Rock Arkansas USA
| | - Hong‐yu Li
- Department of Pharmaceutical Sciences College of Pharmacy University of Arkansas for Medical Sciences 4301 W Markham St. 72205 Little Rock Arkansas USA
| |
Collapse
|
12
|
Saha D, Kharbanda A, Essien N, Zhang L, Cooper R, Basak D, Kendrick S, Frett B, Li HY. Intramolecular cyclization of imidazo[1,2-a]pyridines via a silver mediated/palladium catalyzed C–H activation strategy. Org Chem Front 2019. [DOI: 10.1039/c9qo00389d] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Intramolecular cyclization of imidazo[1,2-a]pyridines has been developed via a C–H activation strategy to reach new chemical-space for drug discovery.
Collapse
Affiliation(s)
- Debasmita Saha
- Department of Pharmaceutical Sciences
- College of Pharmacy
- University of Arkansas for Medical Sciences
- Little Rock
- USA
| | - Anupreet Kharbanda
- Department of Pharmaceutical Sciences
- College of Pharmacy
- University of Arkansas for Medical Sciences
- Little Rock
- USA
| | - Nkeseobong Essien
- Department of Pharmaceutical Sciences
- College of Pharmacy
- University of Arkansas for Medical Sciences
- Little Rock
- USA
| | - Lingtian Zhang
- Department of Pharmaceutical Sciences
- College of Pharmacy
- University of Arkansas for Medical Sciences
- Little Rock
- USA
| | - Rose Cooper
- Department of Pharmaceutical Sciences
- College of Pharmacy
- University of Arkansas for Medical Sciences
- Little Rock
- USA
| | - Debasish Basak
- Department of Biochemistry and Molecular Biology
- College of Medicine
- University of Arkansas for Medical Sciences
- Little Rock
- USA
| | - Samantha Kendrick
- Department of Biochemistry and Molecular Biology
- College of Medicine
- University of Arkansas for Medical Sciences
- Little Rock
- USA
| | - Brendan Frett
- Department of Pharmaceutical Sciences
- College of Pharmacy
- University of Arkansas for Medical Sciences
- Little Rock
- USA
| | - Hong-yu Li
- Department of Pharmaceutical Sciences
- College of Pharmacy
- University of Arkansas for Medical Sciences
- Little Rock
- USA
| |
Collapse
|
13
|
Frett B, McConnell N, Kharbanda A, Naresh G, Rounseville B, Warner C, Chang J, Debolske N, Li HY. Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2- a]pyridine derivatives. Tetrahedron 2018; 74:4592-4600. [PMID: 30344351 PMCID: PMC6192254 DOI: 10.1016/j.tet.2018.07.027] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Carbon-carbon bonds are integral for pharmaceutical discovery and development. Frequently, C-C bond reactions utilize expensive catalyst/ligand combinations and/or are low yielding, which can increase time and expenditures in pharmaceutical development. To enhance C-C bond formation protocols, we developed a highly efficient, selective, and combinatorially applicable Friedel-Crafts acylation to acetylate the C-3 position of imidazo[1,2-a]pyridines. The reaction, catalyzed by aluminum chloride, is both cost effective and more combinatorial friendly compared to acetylation reactions requiring multiple, stoichiometric equivalents of AlCl3. The protocol has broad application in the construction of acetylated imidazo[1,2-a]pyridines with an extensive substrate scope. All starting materials are common and the reaction requires inexpensive, conventional heating methods for adaptation in any laboratory. Further, the synthesized compounds are predicted to possess GABA activity through a validated, GABA binding model. The developed method serves as a superior route to generate C-3 acetylated imidazo[1,2-a]pyridine building-blocks for combinatorial synthetic efforts.
Collapse
Affiliation(s)
- Brendan Frett
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
| | - Nicholas McConnell
- College of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, 1703 E. Mabel, Tucson, AZ 85721, USA
| | - Anupreet Kharbanda
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
| | - Gunaganti Naresh
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
| | - Benjamin Rounseville
- College of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, 1703 E. Mabel, Tucson, AZ 85721, USA
| | - Christina Warner
- College of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, 1703 E. Mabel, Tucson, AZ 85721, USA
| | - John Chang
- College of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, 1703 E. Mabel, Tucson, AZ 85721, USA
| | - Natalie Debolske
- College of Pharmacy, Department of Pharmacology and Toxicology, The University of Arizona, 1703 E. Mabel, Tucson, AZ 85721, USA
| | - Hong-yu Li
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
| |
Collapse
|
14
|
Bharate JB, McConnell N, Naresh G, Zhang L, Lakkaniga NR, Ding L, Shah NP, Frett B, Li HY. Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. Sci Rep 2018; 8:3722. [PMID: 29487300 PMCID: PMC5829162 DOI: 10.1038/s41598-018-21839-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Accepted: 02/12/2018] [Indexed: 12/19/2022] Open
Abstract
FMS-like Tyrosine Kinase 3 (FLT3) is a clinically validated target for acute myeloid leukemia (AML). Inhibitors targeting FLT3 have been evaluated in clinical studies and have exhibited potential to treat FLT3-driven AML. A frequent, clinical limitation is FLT3 selectivity, as concomitant inhibition of FLT3 and c-KIT is thought to cause dose-limiting myelosuppression. Through a rational design approach, novel FLT3 inhibitors were synthesized employing a pyridine/pyrimidine warhead. The most potent compound identified from the studies is compound 13a, which exhibited an IC50 value of 13.9 ± 6.5 nM against the FLT3 kinase with high selectivity over c-KIT. Mechanism of action studies suggested that 13a is a Type-II kinase inhibitor, which was also supported through computer aided drug discovery (CADD) efforts. Cell-based assays identified that 13a was potent on a variety of FLT3-driven cell lines with clinical relevance. We report herein the discovery and therapeutic evaluation of 4,6-diamino pyrimidine-based Type-II FLT3 inhibitors, which can serve as a FLT3-selective scaffold for further clinical development.
Collapse
Affiliation(s)
- Jaideep B Bharate
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
| | - Nicholas McConnell
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, 72205, USA.,Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ, 85721, USA
| | - Gunaganti Naresh
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
| | - Lingtian Zhang
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
| | - Naga Rajiv Lakkaniga
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
| | - Lucky Ding
- Division of Hematology/Oncology, University of California, San Francisco, CA, 94143, USA
| | - Neil P Shah
- Division of Hematology/Oncology, University of California, San Francisco, CA, 94143, USA.,Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94115, USA
| | - Brendan Frett
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
| | - Hong-Yu Li
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, 72205, USA.
| |
Collapse
|
15
|
McConnell N, Xu Z, Kumarasamy V, Sun D, Frett B, Li HY. Synthesis of Constrained Heterocycles Employing Two Post-Ugi Cyclization Methods for Rapid Library Generation with In Cellulo Activity. ChemistrySelect 2017; 2:11821-11825. [PMID: 30140731 PMCID: PMC6103208 DOI: 10.1002/slct.201702179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Accepted: 11/20/2017] [Indexed: 01/10/2024]
Abstract
Benzimidazoles and quinoxalinones are present in the core of many pharmacologically relevant compounds. Several combinatorial methods have been developed to attach ring systems to both scaffolds for derivatization at select positions. Herein, we describe the development of novel constrained heterocyclic compounds attached to the N1 position of both benzimidazole and quinoxalinone scaffolds. Utilizing robust post-Ugi cyclization methods, including the Ugi-deprotection-cyclization (UDC) methodology, allows for efficient access to a new area of chemical space. Additionally, molecular modeling and in cellulo screening was employed to therapeutically validate the compounds formed with this method.
Collapse
Affiliation(s)
- Nicholas McConnell
- Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona 85719 United States
| | - Zhigang Xu
- International Academy of Targeted Therapeutics and Innovation Chongqing University of Arts and Sciences, 319 Honghe Ave., Yongchuan, Chongqing 402160 China
| | - Vishnu Kumarasamy
- Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona 85719 United States
| | - Daekyu Sun
- Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona 85719 United States
| | - Brendan Frett
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States
| | - Hong-Yu Li
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States
| |
Collapse
|
16
|
Shao T, Gong Z, Su T, Hao W, Che C. A practical and efficient approach to imidazo[1,2- a]pyridine-fused isoquinolines through the post-GBB transformation strategy. Beilstein J Org Chem 2017; 13:817-824. [PMID: 28546839 PMCID: PMC5433183 DOI: 10.3762/bjoc.13.82] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 04/13/2017] [Indexed: 01/05/2023] Open
Abstract
Diversity-oriented synthesis of the biologically intriguing imidazo[1,2-a]pyridine-fused isoquinoline systems from readily available starting materials was achieved through the Groebke–Blackburn–Bienaymé reaction followed by a gold-catalyzed cyclization strategy. The synthetic approach is characterized by mild reaction conditions and a broad substrate scope, allowing for the rapid construction of structurally complex and diverse heterocycles in moderate to good yields.
Collapse
Affiliation(s)
- Taofeng Shao
- Laboratory of Chemical Genomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| | - Zhiming Gong
- Laboratory of Chemical Genomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| | - Tianyi Su
- Laboratory of Chemical Genomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| | - Wei Hao
- Laboratory of Chemical Genomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| | - Chao Che
- Laboratory of Chemical Genomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| |
Collapse
|
17
|
Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Eur J Med Chem 2017; 126:1083-1106. [DOI: 10.1016/j.ejmech.2016.12.026] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Revised: 12/09/2016] [Accepted: 12/11/2016] [Indexed: 11/21/2022]
|
18
|
Yang B, Tao C, Shao T, Gong J, Che C. One-pot synthesis of tetracyclic fused imidazo[1,2-a]pyridines via a three-component reaction. Beilstein J Org Chem 2016; 12:1487-92. [PMID: 27559401 PMCID: PMC4979633 DOI: 10.3762/bjoc.12.145] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Accepted: 06/29/2016] [Indexed: 12/25/2022] Open
Abstract
A novel three-component reaction has been developed to assemble biologically and pharmaceutically important tetracyclic fused imidazo[1,2-a]pyridines in a one-pot fashion utilizing readily available 2-aminopyridines, isatins and isocyanides. The three-component coupling proceeds through the Groebke–Blackburn–Bienaymé reaction followed by a retro-aza-ene reaction and subsequent nucleophilic reaction of the in-situ generated imidazo[1,2-a]pyridines bearing an isocyanate functional group.
Collapse
Affiliation(s)
- Bo Yang
- Laboratory of Chemical Genomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| | - Chuanye Tao
- Laboratory of Chemical Genomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| | - Taofeng Shao
- Laboratory of Chemical Genomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| | - Jianxian Gong
- Laboratory of Chemical Genomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| | - Chao Che
- Laboratory of Chemical Genomics, Engineering Laboratory for Chiral Drug Synthesis, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| |
Collapse
|
19
|
Firmansyah D, Deperasińska I, Vakuliuk O, Banasiewicz M, Tasior M, Makarewicz A, Cyrański MK, Kozankiewicz B, Gryko DT. Double head-to-tail direct arylation as a viable strategy towards the synthesis of the aza-analog of dihydrocyclopenta[hi]aceanthrylene – an intriguing antiaromatic heterocycle. Chem Commun (Camb) 2016; 52:1262-5. [DOI: 10.1039/c5cc08716c] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Straightforwardly prepared head-to-tail bis-imidazo[1,2-a]pyridine displays antiaromaticity and no fluorescence.
Collapse
Affiliation(s)
| | | | - Olena Vakuliuk
- Institute of Organic Chemistry
- Polish Academy of Sciences
- 01-224 Warsaw
- Poland
| | | | - Mariusz Tasior
- Institute of Organic Chemistry
- Polish Academy of Sciences
- 01-224 Warsaw
- Poland
| | - Artur Makarewicz
- Institute of Physics
- Polish Academy of Sciences
- 02-668 Warsaw
- Poland
| | | | | | - Daniel T. Gryko
- Warsaw University of Technology
- 00-664 Warsaw
- Poland
- Institute of Organic Chemistry
- Polish Academy of Sciences
| |
Collapse
|
20
|
Karale UB, Kalari S, Shivakumar J, Makane VB, Babar DA, Thakare RP, Babu BN, Chopra S, Rode HB. Ligand-free Pd-catalysed decarboxylative arylation of imidazo[1,2-a]pyridine-3-carboxylic acids with aryl bromides. RSC Adv 2016. [DOI: 10.1039/c6ra12166g] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A facile ligand-free method for Pd(OAc)2 catalysed decarboxylative arylation of imidazo[1,2-a]pyridine-3-carboxylic acids with hetero(aryl) bromides has been developed.
Collapse
Affiliation(s)
- Uttam B. Karale
- Department of Natural Product Chemistry
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
- Academy of Scientific and Innovative Research (AcSIR)
| | - Saradhi Kalari
- Department of Natural Product Chemistry
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
| | - Jala Shivakumar
- Department of Medicinal Chemistry
- National Institute of Pharmaceutical Education and Research
- Hyderabad-500 037
- India
| | - Vitthal B. Makane
- Department of Natural Product Chemistry
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
- Academy of Scientific and Innovative Research (AcSIR)
| | - Dattatraya A. Babar
- Department of Natural Product Chemistry
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
- Academy of Scientific and Innovative Research (AcSIR)
| | - Ritesh P. Thakare
- Microbiology Division
- Central Drug Research Institute
- Lucknow-226 031
- India
| | - Bathini Nagendra Babu
- Department of Medicinal Chemistry
- National Institute of Pharmaceutical Education and Research
- Hyderabad-500 037
- India
| | - Sidharth Chopra
- Microbiology Division
- Central Drug Research Institute
- Lucknow-226 031
- India
| | - Haridas B. Rode
- Department of Natural Product Chemistry
- CSIR-Indian Institute of Chemical Technology
- Hyderabad-500007
- India
- Academy of Scientific and Innovative Research (AcSIR)
| |
Collapse
|